Danaher (NYSE:DHR) had its price target upped by Morgan Stanley from $122.00 to $126.00 in a research report report published on Wednesday. They currently have an overweight rating on the conglomerate’s stock.
A number of other analysts also recently weighed in on DHR. Zacks Investment Research downgraded shares of Danaher from a hold rating to a sell rating in a report on Wednesday, June 20th. ValuEngine downgraded shares of Danaher from a buy rating to a hold rating in a report on Thursday, June 21st. Bank of America set a $113.00 target price on shares of Danaher and gave the stock a buy rating in a report on Thursday, July 19th. Finally, Royal Bank of Canada boosted their target price on shares of Danaher to $107.00 and gave the stock a positive rating in a report on Thursday, July 19th. They noted that the move was a valuation call. One analyst has rated the stock with a hold rating and fifteen have given a buy rating to the stock. Danaher has an average rating of Buy and an average price target of $111.57.
Shares of DHR stock opened at $103.38 on Wednesday. The firm has a market capitalization of $76.04 billion, a price-to-earnings ratio of 25.65, a P/E/G ratio of 2.08 and a beta of 1.01. Danaher has a 52 week low of $83.81 and a 52 week high of $110.13. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.07 and a current ratio of 1.50.
The business also recently announced a quarterly dividend, which will be paid on Friday, October 26th. Shareholders of record on Friday, September 28th will be paid a $0.16 dividend. The ex-dividend date is Thursday, September 27th. This represents a $0.64 dividend on an annualized basis and a yield of 0.62%. Danaher’s dividend payout ratio is currently 15.88%.
In other Danaher news, EVP William K. Daniel sold 103,086 shares of the company’s stock in a transaction dated Friday, August 10th. The shares were sold at an average price of $100.63, for a total value of $10,373,544.18. Following the transaction, the executive vice president now directly owns 167,080 shares in the company, valued at approximately $16,813,260.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Daniel L. Comas sold 77,407 shares of the company’s stock in a transaction dated Thursday, July 26th. The stock was sold at an average price of $103.93, for a total transaction of $8,044,909.51. Following the completion of the transaction, the chief financial officer now owns 135,218 shares in the company, valued at $14,053,206.74. The disclosure for this sale can be found here. Insiders sold a total of 299,961 shares of company stock worth $30,619,691 over the last 90 days. Insiders own 11.90% of the company’s stock.
Hedge funds have recently modified their holdings of the business. FMR LLC lifted its position in shares of Danaher by 10.3% in the 2nd quarter. FMR LLC now owns 21,011,026 shares of the conglomerate’s stock worth $2,073,369,000 after purchasing an additional 1,963,116 shares during the period. Putnam Investments LLC lifted its position in shares of Danaher by 0.8% in the 2nd quarter. Putnam Investments LLC now owns 6,385,003 shares of the conglomerate’s stock worth $630,072,000 after purchasing an additional 51,596 shares during the period. Aristotle Capital Management LLC lifted its position in shares of Danaher by 3.5% in the 1st quarter. Aristotle Capital Management LLC now owns 4,451,816 shares of the conglomerate’s stock worth $435,877,000 after purchasing an additional 150,343 shares during the period. Findlay Park Partners LLP lifted its position in shares of Danaher by 4.8% in the 2nd quarter. Findlay Park Partners LLP now owns 3,825,000 shares of the conglomerate’s stock worth $377,451,000 after purchasing an additional 175,000 shares during the period. Finally, Schroder Investment Management Group lifted its position in shares of Danaher by 0.3% in the 2nd quarter. Schroder Investment Management Group now owns 2,765,853 shares of the conglomerate’s stock worth $272,768,000 after purchasing an additional 9,606 shares during the period. Institutional investors and hedge funds own 76.90% of the company’s stock.
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company's Life Sciences segment provides laser scanning, compound, surgical, and other stereo microscopes. This segment also offers filtration, separation, and purification technologies to the biopharmaceutical, food and beverage, medical, aerospace, microelectronics, and general industrial sectors.
Featured Story: How Do You Calculate Return on Equity (ROE)?
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.